## Lupin Limited (LUPIN) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Lupin Limited is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since September 10, 2001.  It operates in the Pharmaceuticals & Biotechnology industry and holds a significant position within the Indian pharmaceutical sector, known for its generic and specialty drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price              | ₹2,149.75       |                                                                      |
| Percentage Change (PChange) | -0.61%          | Negative change indicating a slight downward trend in the day's trading. |
| Pre-Open Activity          | ₹2,165          | Higher than the previous close, suggesting initial buying interest.     |
| Week High                   | ₹2,312          | High point reached during the week.                                  |
| Week Low                    | ₹1,200.15       | Low point reached during the week, indicating significant volatility. |
| VWAP                        | ₹2,161.83       | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 37.21           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 37.21           | Price-to-Earnings ratio for Lupin Limited.                           |
| Delivery Percentage         | 49.24%          | Relatively high delivery percentage suggests some degree of conviction in trades. |
| Market Depth                | Low              | Order book data shows low market depth, indicating potential for price swings. |


**3. Financial Performance:**

The following table summarizes Lupin's financial performance over the past five quarters (figures in ₹ Crores):

| Quarter Ending      | Revenue      | Expenditure  | Profit After Tax | Diluted EPS |
|----------------------|---------------|---------------|--------------------|-------------|
| 30-Sep-2024 (U)     | 413.88        | 315.48        | 80.78             | 17.71       |
| 30-Jun-2024 (U)     | 420.59        | 312.29        | 88.92             | 19.51       |
| 31-Mar-2024 (A)     | 342.72        | 299.91        | 38.41             | 8.43        |
| 31-Dec-2023 (U)     | 413.89        | 305.49        | 91.64             | 20.14       |
| 30-Sep-2023 (U)     | 368.48        | 298.88        | 54.86             | 12.06       |

**(U) - Unaudited, (A) - Audited**

* **Revenue:** Shows some fluctuation but generally positive trend over the past five quarters.
* **Expenditure:** Relatively stable.
* **Profit After Tax:** Fluctuates significantly, indicating potential volatility in profitability.
* **Diluted EPS:** Mirrors the trend in Profit After Tax, showing inconsistency.

**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data limits a comprehensive ratio analysis.

**4. Corporate Actions and Announcements:**

* **Dividends:** Lupin has a history of consistent dividend payouts, with the most recent being ₹8 per share (ex-date July 16, 2024).
* **Announcements:** Recent announcements include information on capital alteration, ESOPs, rumour verifications, press releases, and share certificate issues.  These announcements don't appear to have significantly impacted the stock price in the short term.  Noteworthy is the slump sale of the generic business in India and the transfer of manufacturing sites to subsidiaries.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|-----------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023     | 47.06%                     | 52.94% | 0.00%                         | 100.00%|
| 31-Dec-2023     | 47.04%                     | 52.96% | 0.00%                         | 100.00%|
| 31-Mar-2024     | 47.01%                     | 52.99% | 0.00%                         | 100.00%|
| 30-Jun-2024     | 46.98%                     | 53.02% | 0.00%                         | 100.00%|
| 30-Sep-2024     | 46.96%                     | 53.04% | 0.00%                         | 100.00%|

Promoter holding has shown a slight downward trend over the past year, while public holding has increased correspondingly. This is a relatively minor change and doesn't suggest a significant shift in control.

**6. Volatility and Risk Assessment:**

The week's high and low prices (₹2,312 and ₹1,200.15 respectively) indicate substantial volatility. The CM Annual Volatility of 31.91% further confirms this high-risk profile.  The low market depth adds to the risk, as large orders could easily move the price.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Established presence in the pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility and risk.
* Inconsistent profitability.
* Low market depth.
* Recent slump sales of business units may indicate strategic shifts that could negatively impact future performance.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price is near the VWAP, and the recent downward trend and low market depth suggest caution.  Waiting for clearer price direction is advisable.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the success of the strategic shifts (slump sales) and the overall performance of the pharmaceutical sector.  Further monitoring of financial results is crucial.

* **Long-term (1 year and beyond): Hold/Don't Buy.**  The long-term prospects depend on Lupin's ability to adapt to market changes and maintain a competitive edge.  Given the current volatility and uncertainty surrounding recent corporate actions, a "Hold" or "Don't Buy" recommendation is more prudent until further information is available.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* **Financial Health (out of 10): 5.0**  Inconsistent profitability and lack of comprehensive ratio analysis limit the score.
* **Market Performance (out of 10): 4.0** High volatility and recent negative price movement.
* **Volatility and Risk (out of 10): 3.0** High volatility and low market depth contribute to high risk.
* **Corporate Actions and Governance (out of 10): 7.0** Consistent dividend payouts and transparent announcements.
* **Shareholding Patterns (out of 10): 8.0** Stable shareholding pattern with minor changes.

**Analysis Score (out of 10): 9.0**

* **Data Utilization (out of 10): 10.0** All provided data points were used in the analysis.
* **Accuracy and Clarity (out of 10): 9.0** Analysis is clear and well-structured, but some limitations due to incomplete financial data.
* **Professional Formatting (out of 10): 9.0** Report is professionally formatted and easy to read.


**11. Professional Recommendation Summary:**

Based on the analysis of available data, Lupin Limited presents a mixed investment picture. While the company has a history of dividend payouts and a strong presence in the pharmaceutical sector, the high volatility, inconsistent profitability, and recent strategic shifts introduce significant risk.  Therefore, a cautious approach is recommended.  For short-term and medium-term horizons, a "Hold" strategy is suggested, pending further clarification on the impact of recent corporate actions.  For the long term, a "Hold" or "Don't Buy" is recommended until a clearer picture of the company's future performance emerges.  Further investigation into the company's financial statements and future strategic plans is strongly advised before making any investment decisions.
